Source comparison
BPC-157 Gastric Protection Results Timeline Expect: Comparison
BPC-157 VEGF/FGF upregulation, angiogenesis, NOS modulation 3–7 days (mucosa stabilisation) 14–28 days (epithelial closure) Unknown. Limited long-term human data Most direct pro-regenerative mechanism; lacks standardised dosing protocols Proton Pump Inhibitors
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF/FGF upregulation, angiogenesis, NOS modulation
- 3–7 days (mucosa stabilisation)
- 14–28 days (epithelial closure)
- Unknown. Limited long-term human data
- Most direct pro-regenerative mechanism; lacks standardised dosing protocols
- Proton Pump Inhibitors (omeprazole, pantoprazole)
- Irreversible H+/K+-ATPase inhibition, 90–95% acid suppression
- 1–3 days (symptom relief)
- 28–56 days (complete healing)
- 25–40% within 6 months
- Gold standard for acid suppression but doesn't address epithelial repair mechanisms
- H2 Receptor Antagonists (ranitidine, famotidine)
- Competitive histamine receptor blockade, 60–70% acid reduction
- 1–2 days (symptom relief)
- 42–84 days (variable healing)
- 35–50% within 6 months
- Less potent than PPIs; healing timelines significantly longer
- Sucralfate
- Aluminium complex barrier formation over ulcerated tissue
- 2–5 days (protective coating)
- 28–42 days (passive healing under barrier)
- 20–30% within 6 months
- Physical protection without active regeneration. Slower than angiogenic approaches
- L-Glutamine Supplementation
- Enterocyte fuel source, enhances mucosal barrier integrity
- 7–14 days (barrier improvement)
- 35–56 days (supportive, not primary therapy)
- Baseline risk. No direct healing mechanism
- Supportive adjunct; insufficient as monotherapy for active ulceration
- BPC-157 operates through a fundamentally different pathway than acid suppression therapies. PPIs reduce the damage mechanism (acid exposure) but don't actively accelerate tissue repair beyond what passive healing provides. BPC-157 targets the repair mechanisms directly. Upregulating growth factors, enhancing angiogenesis, and modulating inflammation. The timeline advantage comes from this dual action: stabilising existing damage while simultaneously accelerating regenerative processes.